Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 13/20 | 0.44 |
| ▸ | PPARA | Q07869 | 11/20 | 0.44 |
| ▸ | GPR88 | Q9GZN0 | 6/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1826873 | 0.81 | PGR (0.61) | PPARGPPARAGPR88PPARDPGR | |
| SCHEMBL10211681 | 0.81 | PGR (0.61) | PPARGPPARAGPR88PPARDPGR | |
| SCHEMBL10211683 | 0.81 | PGR (0.61) | PPARGPPARAGPR88PPARDPGR | |
| SCHEMBL14311443 | 0.81 | GPR88 (0.57) | PPARGPPARAGPR88PPARD | |
| SCHEMBL6076509 | 0.78 | PPARG (0.54) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL1338568 | 0.78 | PPARG (0.64) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL1822674 | 0.78 | PPARG (0.55) | PPARGPPARAPPARDPGRADORA3 | |
| SCHEMBL5432245 | 0.77 | PPARG (0.73) | PPARGPPARAGPR88PPARD | |
| SCHEMBL5432240 | 0.77 | PPARG (0.73) | PPARGPPARAGPR88PPARD | |
| SCHEMBL4827455 | 0.77 | PPARG (0.73) | PPARGPPARAGPR88PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041837-B2 | Heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILLA HEALTHCARE LIMITED (IN) | 2006-05-09 | — | — | US | disclosed |
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | CADILA HEALTHCARE LIMITED (IN) | 2003-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236254-A1 | Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine | LIPA, LIPC, CYP46A1 | PPARG 129/4885PPARA 68/4885GPR88 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.